A new study published in the Annals of Internal Medicine suggests that healthcare providers aren’t prescribing these new options as much as they should.
A U.S. and Canada study shows that ASA 300 mg daily does not improve risk of breast cancer recurrence or survival in individuals with high-risk nonmetastatic breast cancer.